Issue: November 2010
November 01, 2010
1 min read

Investigational drug reduced bone resorption markers, increased BMD

Issue: November 2010
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

ASBMR Annual Meeting

Postmenopausal women assigned to an investigational cathepsin-K inhibitor called odanacatib experienced reductions in bone resorption markers and progressive increases in bone mineral density during 4 years of treatment.

Treatment with odanacatib 50 mg weekly (Merck) for 4 years was associated with an increase in BMD of 2.8% at the lumbar and 2.7% at the hip between years 3 and 4 of treatment. During 4 years of treatment, women in the odanacatib arm had increases in lumbar spine (10.7%) and hip (8.3%) BMD from baseline.

Levels of serum CTx (–41% from baseline) remained low, whereas BSAP (–2% from baseline) remained relatively unchanged between years 3 and 4 of the study.

In women who received odanacatib for 2 years during the base study but were switched to placebo for the 2-year extension (n=38), the effects on bone turnover markers and BMD were reversed, returning to, or near, baseline.

The most frequently reported adverse events during the 4-year extension included nasopharyngitis (13% vs. 17%) and pain in the extremities (10% vs. 2.4%) compared with placebo.

Odanacatib is currently in phase 3 clinical trials and is being evaluated in a large-scale clinical study to determine the potential effects on vertebral, non-vertebral and hip fractures.

For more information:

  • Binkley N. Concurrent oral session 42: Osteoporosis treatment – pharmacologic and nonpharmacologic. #1247. Presented at: American Society of Bone and Mineral Research 2010 Annual Meeting; Oct. 15-19, 2010; Toronto.

Twitter Follow on Twitter.